<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FA143EC1-E637-4E0C-80ED-0EA8ED214038"><gtr:id>FA143EC1-E637-4E0C-80ED-0EA8ED214038</gtr:id><gtr:name>University of Leuven</gtr:name><gtr:address><gtr:line1>Oude Markt 13</gtr:line1><gtr:line2>Box 5005</gtr:line2><gtr:region>outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C7FBE408-C743-4AAC-9BC6-65E14BC8D2FD"><gtr:id>C7FBE408-C743-4AAC-9BC6-65E14BC8D2FD</gtr:id><gtr:name>Karolinska Institute</gtr:name><gtr:address><gtr:line1>Administration</gtr:line1><gtr:line4>Stockholm</gtr:line4><gtr:postCode>SE-171 77</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2F6044B9-9BC3-4ABA-9115-6AA15854A44A"><gtr:id>2F6044B9-9BC3-4ABA-9115-6AA15854A44A</gtr:id><gtr:name>University of Basel</gtr:name><gtr:address><gtr:line1>Petersplatz 1</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Switzerland</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/89D5574C-AAF7-4D96-832C-C2BA623123CE"><gtr:id>89D5574C-AAF7-4D96-832C-C2BA623123CE</gtr:id><gtr:name>Eberhard Karls University Tuebingen</gtr:name><gtr:address><gtr:line1>Wilhelmstra?e 7</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/15D3C1D3-84F0-48E8-8480-71DDFF4D82C5"><gtr:id>15D3C1D3-84F0-48E8-8480-71DDFF4D82C5</gtr:id><gtr:name>Children's Hospital Oakland Research Institute (CHORI)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/AB307619-D4FA-427E-A042-09DBEBA84669"><gtr:id>AB307619-D4FA-427E-A042-09DBEBA84669</gtr:id><gtr:name>Swansea University</gtr:name><gtr:department>Institute of Life Science Medical School</gtr:department><gtr:address><gtr:line1>Singleton Park</gtr:line1><gtr:postCode>SA2 8PP</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AB307619-D4FA-427E-A042-09DBEBA84669"><gtr:id>AB307619-D4FA-427E-A042-09DBEBA84669</gtr:id><gtr:name>Swansea University</gtr:name><gtr:address><gtr:line1>Singleton Park</gtr:line1><gtr:postCode>SA2 8PP</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/798CB33D-C79E-4578-83F2-72606407192C"><gtr:id>798CB33D-C79E-4578-83F2-72606407192C</gtr:id><gtr:name>EPSRC</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:line4>Swindon</gtr:line4><gtr:line5>Wiltshire</gtr:line5><gtr:postCode>SN2 1ET</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>CO_FUNDER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FA143EC1-E637-4E0C-80ED-0EA8ED214038"><gtr:id>FA143EC1-E637-4E0C-80ED-0EA8ED214038</gtr:id><gtr:name>University of Leuven</gtr:name><gtr:address><gtr:line1>Oude Markt 13</gtr:line1><gtr:line2>Box 5005</gtr:line2><gtr:region>outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C7FBE408-C743-4AAC-9BC6-65E14BC8D2FD"><gtr:id>C7FBE408-C743-4AAC-9BC6-65E14BC8D2FD</gtr:id><gtr:name>Karolinska Institute</gtr:name><gtr:address><gtr:line1>Administration</gtr:line1><gtr:line4>Stockholm</gtr:line4><gtr:postCode>SE-171 77</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2F6044B9-9BC3-4ABA-9115-6AA15854A44A"><gtr:id>2F6044B9-9BC3-4ABA-9115-6AA15854A44A</gtr:id><gtr:name>University of Basel</gtr:name><gtr:address><gtr:line1>Petersplatz 1</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Switzerland</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/89D5574C-AAF7-4D96-832C-C2BA623123CE"><gtr:id>89D5574C-AAF7-4D96-832C-C2BA623123CE</gtr:id><gtr:name>Eberhard Karls University Tuebingen</gtr:name><gtr:address><gtr:line1>Wilhelmstra?e 7</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/15D3C1D3-84F0-48E8-8480-71DDFF4D82C5"><gtr:id>15D3C1D3-84F0-48E8-8480-71DDFF4D82C5</gtr:id><gtr:name>Children's Hospital Oakland Research Institute (CHORI)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/5DBBB01C-06B9-4BA5-A0E0-F9F9D78C882F"><gtr:id>5DBBB01C-06B9-4BA5-A0E0-F9F9D78C882F</gtr:id><gtr:firstName>Yuqin</gtr:firstName><gtr:surname>Wang</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/E3533D19-36C6-4B5D-BEA8-B92FAEDE8A9D"><gtr:id>E3533D19-36C6-4B5D-BEA8-B92FAEDE8A9D</gtr:id><gtr:firstName>William</gtr:firstName><gtr:otherNames>James</gtr:otherNames><gtr:surname>Griffiths</gtr:surname><gtr:orcidId>0000-0002-4129-6616</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BB%2FI001735%2F1"><gtr:id>41404D51-6143-4B2A-9596-CD1074C7F693</gtr:id><gtr:title>An Integrated platform for Quantitative Sterolomics: From Oxysterols to Bile Acids and Steroids</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/I001735/1</gtr:grantReference><gtr:abstractText>Cholesterol is an essential component of every animal cell. It is a structural lipid in cell membranes and the precursor of oxysterols, bile acids and steroid hormones. Cellular cholesterol homeostasis is maintained by the balance between cholesterol absorption, biosynthesis and metabolism. The first step of all cholesterol metabolism is oxidation to an oxysterol. Oxysterols are oxygenated derivatives of cholesterol which in the past have been regarded as transport forms of cholesterol returning it to the liver for conversion to bile acids. However, recent data indicates that oxysterols have biological activity, mediating a number of cholesterol-induced metabolic effects. Furthermore, down-stream acidic cholesterol metabolites, biosynthesised by many different cell types, are also biologically active. New results show that oxysterols are involved in many areas of biology e.g. acting to reduce proliferation of progenitor cells in developing brain, reducing proliferation of naive B cells and blocking class switch recombination in the immune system, offering protection against neurodegenerative disease and memory loss, and showing differential expression in malignant cells. Furthermore, bile acids, recycled by the enterohepatic system, have been shown to act as hormones by activating the G protein coupled receptor TGR5 and triggering an increase in energy expenditure and attenuation of diet-induced obesity. It is important to realise that oxysterols are a class of molecule consisting of a wide-range of distinct chemical entities. This is also true of their down-stream metabolites, and is a consequence of the initial oxidation reaction occurring at any one of many potential sites on the cholesterol molecule and the order of subsequent enzymatic biotransformations being variable. This leads to a multitude of possible metabolites. This complexity is similarly reflected in bile acids which can be structurally-transformed by bacteria in the enterohepatic system. Cholesterol metabolites are challenging molecules to analyse in biological systems. This is a consequence of their low abundance against a high background of cholesterol (e.g. ng oxysterol / microg cholesterol in brain, ng bile acid / mg cholesterol in plasma, pg neurosteroid / microg cholesterol in CSF), the propensity of cholesterol to be oxidised in air to oxysterols (and also to C19 &amp;amp; C21 steroids) there-by generating analytical artefacts, and their lack of a strong chromophore but thermal lability. The consequence of this is that comprehensive cholesterol metabolite profiles are poorly described in body fluids, tissues and cell types. In this proposal we intend to meet this challenge by developing an integrated mass spectrometry-based platform for the ultra-high sensitivity quantitative and structural determination of cholesterol metabolites in biological systems. We will introduce new technology based on chemical-tagging to enhance the analysis of cholesterol metabolites, their structural determination, and quantification. By exploiting stable-isotope labelling in the charge-tags we will be able to determine absolute quantities of specific metabolites and also perform relative quantification of untargeted metabolites between different samples e.g. between different locations in brain or between different cell types. Through international collaboration we will investigate the biological activity of the identified metabolites in defined biological assays. This project is likely to have impact with respect to healthy aging, and as deranged cholesterol synthesis and metabolism is implicated in numerous disease states (neurodegenerative disease; atherosclerosis; diabetes) and malformation syndromes will be of benefit to UK pharma and those involved in biomarker discovery and clinical screening.</gtr:abstractText><gtr:technicalSummary>The primary objective of the current proposal is to develop an integrated mass spectrometry (MS)-based platform for the quantitative and structural determination of cholesterol metabolites in biological systems. This will be supplemented by assays of their bioactivity. Over the last 20 years the focus of the PI's research has been the identification and quantification of oxysterols, bile acids and steroids in body fluids, tissues and cell types. While many molecules in these classes can be analysed at high sensitivity in targeted analysis by MS, usually utilising multiple reaction monitoring (MRM) or selected-ion recording (SIR), such analysis require pre-defined targets and are not suitable for profile analysis or the identification of unknown or unexpected components. Furthermore accurate quantification requires an isotope-labelled internal standard. In recent years we have developed an alternative strategy based on charge-tagging and LC-MSn for the ultra-high sensitivity identification and quantification of cholesterol metabolites. By utilising simple chemistry we tag a charged group to a ketone group on cholesterol metabolites, this improves the LC-MS response by two - three orders of magnitude. Further, the nature of the derivative enhances the information content of MSn spectra, allowing structure determination and identification of unknowns. In this proposal we seek to move this methodology to the next level by incorporating stable-isotope labelling in the charge-tag thereby allowing absolute quantification of individual samples and relative quantification between samples. Further, we will extend the number of metabolites amenable to charge-tagging by incorporating enzymatic conversion of alcohol functions to ketone groups (thus available for derivatisation).</gtr:technicalSummary><gtr:potentialImpactText>The primary objective of the current proposal is to develop an integrated mass spectrometry (MS)-based platform for the quantitative and structural determination of cholesterol metabolites in biological systems. As part of this proposal we will create a series of isotope-coded charge tags for use in ultra-high sensitivity quantitative studies. The isotope-coded charge tags will offer improved analyte sensitivity and allow absolute quantification of defined analytes and relative quantification (between samples) of undefined targets. We will further develop the tagging chemistry to allow charge-tagging to alcohol (3beta and 3alfa hydroxyl groups on the steroid skeleton) functionalities in addition to oxo (ketone/aldehyde) groups. Although in this study we will concentrate our attention on the analysis of cholesterol metabolites, the developed isotope-coded charge tags will be equally useful in other areas of lipidomics and metabolomics. The likely beneficiaries of our analytical platform are analysts working in the areas of metabolomics, lipidomics, biomarker discovery, clinical screening and doping control. The methods generated by the present study will be valuable to those working in the sterol bile acid and steroid fields, including contract research, pharmaceutical companies, and doping and clinical laboratories. The analytical methods are likely to be important in neuroscience, particularly for the prediction and monitoring of neurodegenerative disease, and in stem cell biology, cancer and immunology where specific cholesterol metabolites have been shown to be important in influencing cell proliferation. We will publish our data in peer review journals, make presentations at international meetings and also establish a website where data and methods will be freely available. We will also present our data to the general public at public seminars, open days and visits to schools. With respect to commercialisation we are collaborating with Proteome Sciences plc in the area of isotope-coded tags for tandem mass spectrometry in metabolomics, and we would negotiate with them to commercialisation our isotope-coded charge tags. The research has considerable potential impact on the nation's health and wellbeing. We plan (in future studies) to utilise our analytical platform to validate potential cholesterol derived metabolites as markers for the early diagnosis of Alzheimer's disease. Early diagnosis will be important as new treatments; both pharmacological and psychological are being developed. The research may also have an impact in the development of regenerative therapies for Parkinson's disease as cholesterol metabolites have been found to be important in the development of dopaminergic neurons from stem cells. The PDRA employed in this project will gain an expert education in biological mass spectrometry; which can in the future be exported to all areas of analytical science. Further, the project is at the interface of chemistry, biology and medicine and is thus multidisciplinary. Cholesterol metabolites identified to have biological activity will be patented in association with Swansea University. We will seek to exploit commercially our isotope-coded charge tags in collaboration with Proteome Sciences plc.</gtr:potentialImpactText><gtr:fund><gtr:end>2014-08-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2011-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>326462</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Child Health</gtr:department><gtr:description>ICH: Inborn errors of metabolism</gtr:description><gtr:id>EBC2E093-7D9E-4FC8-B7B5-A90E3B00C726</gtr:id><gtr:impact>Four publications</gtr:impact><gtr:outcomeId>569507a5bef719.88131347-1</gtr:outcomeId><gtr:partnerContribution>Clinical information concerning inborn errors of metabolism</gtr:partnerContribution><gtr:piContribution>Investigation of inborn errors of cholesterol biosynthesis and metabolism.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Basel</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:department>University Hospital Basel</gtr:department><gtr:description>Multiple Sclerosis</gtr:description><gtr:id>46457617-B512-4D4E-BD7C-7DD0CAC4C563</gtr:id><gtr:impact>Publications in The Journal of Clinical Investigation (2014) and Molecular Neurobiology (2016)</gtr:impact><gtr:outcomeId>58a57404d5fd95.81640698-1</gtr:outcomeId><gtr:partnerContribution>Expertise in multiple sclerosis pathology</gtr:partnerContribution><gtr:piContribution>Expertise in sterol and oxysterol analysis.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Manchester</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Manchester: Collaboration on inborn errors of metabolism</gtr:description><gtr:id>5EFD74B3-6BC8-43D5-A730-B737B7E61681</gtr:id><gtr:impact>Three papers have been published</gtr:impact><gtr:outcomeId>5695052d0e2544.94973237-1</gtr:outcomeId><gtr:partnerContribution>Provision of samples for the study of inborn errors of cholesterol biosynthesis and metabolism.</gtr:partnerContribution><gtr:piContribution>Analysis of plasma and urine samples in the study of inborn errors of cholesterol biosynthesis and metabolism.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Edin</gtr:description><gtr:id>3931B8E2-0B4C-4963-9D8C-C4400D4636BF</gtr:id><gtr:impact>Paper in Immunity and PLoS Biology</gtr:impact><gtr:outcomeId>545b54c26d2887.66592355-1</gtr:outcomeId><gtr:partnerContribution>Edinburgh has provided intellectual input and data.</gtr:partnerContribution><gtr:piContribution>We have provided intellectual input and data.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Nuffield Department of Clinical Neurosciences</gtr:department><gtr:description>Motor Neuron Disease</gtr:description><gtr:id>EBCC770F-5165-498B-BD2B-59BD229CE214</gtr:id><gtr:impact>Publication in Journal of Lipid Research 2017</gtr:impact><gtr:outcomeId>58a575942a7d36.71546800-1</gtr:outcomeId><gtr:partnerContribution>Expertise in motor neuron disease clinical pathology</gtr:partnerContribution><gtr:piContribution>Expertise in sterol and oxysterol analysis</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Glasgow</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>College of Arts</gtr:department><gtr:description>Pulmonary Fibrosis</gtr:description><gtr:id>718D55B5-61BB-4AFB-84C6-EB2F46F6C3A0</gtr:id><gtr:impact>Publication in Journal of Allergy and Clinical Immunology (2016)</gtr:impact><gtr:outcomeId>58a577e6c47245.15563724-1</gtr:outcomeId><gtr:partnerContribution>Expertise in the pathology of pulmonary fibrosis</gtr:partnerContribution><gtr:piContribution>Expertise in sterol/oxysterol analysis</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Leuven</gtr:collaboratingOrganisation><gtr:country>Belgium, Kingdom of</gtr:country><gtr:department>Zoological Institute</gtr:department><gtr:description>Peroxisome</gtr:description><gtr:id>24F2BAA4-790D-458E-9617-6DAD58D069B4</gtr:id><gtr:impact>Publications in Steroids (2015), Biochemical Journal (2014)</gtr:impact><gtr:outcomeId>58a57ee539b1e3.59052968-1</gtr:outcomeId><gtr:partnerContribution>Expertise in biochemistry of the peroxisome</gtr:partnerContribution><gtr:piContribution>Expertise in sterol and oxysterol analysis</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Eberhard Karls University of Tubingen</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Centre of Neurology and Hertie-Institute for Clinical Brain Research</gtr:department><gtr:description>Hereditary Spastic Paraplegia</gtr:description><gtr:id>CFD091F0-53F1-47D0-8442-521FB1E19F38</gtr:id><gtr:impact>Publication in The Journal of Clinical Investigation 2014</gtr:impact><gtr:outcomeId>58a57060874566.83887140-1</gtr:outcomeId><gtr:partnerContribution>Hepatocyte and cortical neuron differentiation from iPS cells.
Clinical samples from patients with in born errors of metabolism</gtr:partnerContribution><gtr:piContribution>Expertise in oxysterol and sterol analysis.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Children's Hospital Oakland Research Institute (CHORI)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>CHORI: Inborn errors of metabolism</gtr:description><gtr:id>D63B3FBD-2449-4FE8-97AA-C838B3778878</gtr:id><gtr:impact>Three publications</gtr:impact><gtr:outcomeId>5696306aa9f920.14887894-1</gtr:outcomeId><gtr:partnerContribution>Provision of patient and mouse model samples. Expertise in inborn errors of metabolism.</gtr:partnerContribution><gtr:piContribution>Analysis of patient and mouse model samples.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Karolinska Institute</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>Karolinska</gtr:description><gtr:id>408AFCD2-6C66-4FE9-8422-C6BE543D5D69</gtr:id><gtr:impact>This is a multidisciplinary collaboration between neuroscientists and clinical chemists at Karolinska Institute and analytical scientists in Swansea. This colaboration has resulted in papers in Nature Chemical Biology and the Journal of Clinical Investigation.</gtr:impact><gtr:outcomeId>545b5287896d69.84429444-1</gtr:outcomeId><gtr:partnerContribution>They have brought essential data and insight to the collaboration.
Our partners are bringing transgenic animal material and expertise to the collaboration.</gtr:partnerContribution><gtr:piContribution>We have brought essential data and insight to the collaboration.
We are bringing new technology</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Cholesterol metabolites regulate motor neuron function</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>29910C19-2FED-4440-8133-0A435201AB08</gtr:id><gtr:impact>A research highlight was published in Nature Reviews Endocrinology.

NA</gtr:impact><gtr:outcomeId>5453b32ec07863.18526342</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>http://www.nature.com/nrendo/journal/vaop/ncurrent/full/nrendo.2014.184.html</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ASBMB Cholesterol and ALS</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>336705B9-335C-4193-A29F-5F93289B52D8</gtr:id><gtr:impact>Article in ASBMB monthly magazine</gtr:impact><gtr:outcomeId>58a58c5f7c4443.17387613</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Steroids: Scientists examine controversial substance's potential to treat Parkinson's, http://www.walesonline.co.uk/news/wales-news/steroids-scientists-examine-controversial-substances-2496776</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>891F613F-F0FA-4860-B89C-E6050C763267</gtr:id><gtr:impact>Steroids could be used to treat a debilitating disease that affects thousands in Wales today. Researchers at a University in Wales have highlighted the controversial substance's positive side after discovering two steroid type molecules that could treat Parkinson's disease

no actual impacts realised to date</gtr:impact><gtr:outcomeId>r-9497377722.9873260cc5e1e0</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>New steroid discovery could improve Parkinson's treatment;</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>098CCC0F-C2C6-4BD1-8DF1-42A413439B2D</gtr:id><gtr:impact>Scientists at Swansea University and Karolinska Institutet in Stockholm have identified two steroid-type molecules that play an important role in the survival and production of nerve cells in the brain. 



The discovery, published in the journal Nature Chemical Biology, could help in the development of new treatments for neurological diseases such as Parkinson's disease.

no actual impacts realised to date</gtr:impact><gtr:outcomeId>r-5871081031.7388560cc4a71c</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Cholesterol and ALS</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>393DCE6D-97FF-4BAD-A433-76F162B8A88D</gtr:id><gtr:impact>Press release to communicate latest scientific discovery. Many email responses from motor neuron disease sufferers or carers.</gtr:impact><gtr:outcomeId>58a58baf3606d7.86947425</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>652000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Responsive</gtr:description><gtr:end>2016-06-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:fundingRef>BB/K019112/1</gtr:fundingRef><gtr:id>CE32790B-3996-4E0D-82FD-BE4813578B85</gtr:id><gtr:outcomeId>5ee59c485ee59c5c</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>10954</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Follow on Fund</gtr:description><gtr:end>2014-03-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:fundingRef>BB/FOF/PF/15/13</gtr:fundingRef><gtr:id>A25F1300-C12C-4A8C-A6B8-6D2A5C8282FD</gtr:id><gtr:outcomeId>5ee4924e5ee49262</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>66240</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>A4B</gtr:description><gtr:end>2014-12-02</gtr:end><gtr:fundingOrg>Welsh Assembly</gtr:fundingOrg><gtr:id>C856F190-F687-458A-9F11-F942471CC964</gtr:id><gtr:outcomeId>5453acb7a1a5f8.76346001</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2014-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>53476</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>KESS II</gtr:description><gtr:end>2019-09-02</gtr:end><gtr:fundingOrg>Government of Wales</gtr:fundingOrg><gtr:fundingRef>EGR817</gtr:fundingRef><gtr:id>4121FD06-D48F-41B3-A894-F9F9CA1DA4B6</gtr:id><gtr:outcomeId>58a5881b7955a2.21377110</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2016-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>460386</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BBSRC Responsive mode</gtr:description><gtr:end>2019-09-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:fundingRef>BB/N015932/1</gtr:fundingRef><gtr:id>CD92FA93-7897-4AE2-9272-BB76A51A0C00</gtr:id><gtr:outcomeId>58a585b4cf6b15.96323645</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2016-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>382198</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Responsive Mode</gtr:description><gtr:end>2017-01-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:fundingRef>BB/L001942/1</gtr:fundingRef><gtr:id>40FFBB5F-F9DD-4817-B18F-5F58BFD67012</gtr:id><gtr:outcomeId>5ee5aeae5ee5aec2</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>378057</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>A4B</gtr:description><gtr:end>2014-12-02</gtr:end><gtr:fundingOrg>Government of Wales</gtr:fundingOrg><gtr:fundingRef>HE09161003</gtr:fundingRef><gtr:id>40F42066-5C4F-4256-866E-545CDC203069</gtr:id><gtr:outcomeId>r-9425200623.85611306a6efaa</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Life Sciences Research Network Wales</gtr:description><gtr:end>2016-02-02</gtr:end><gtr:fundingOrg>Government of Wales</gtr:fundingOrg><gtr:id>94A8D206-3763-47B5-A979-182A88B12E4D</gtr:id><gtr:outcomeId>545b59e851f705.35524881</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>36000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>SHIPP INITIATIVE</gtr:description><gtr:end>2017-02-02</gtr:end><gtr:fundingOrg>Government of Wales</gtr:fundingOrg><gtr:fundingRef>SHIPP-0001</gtr:fundingRef><gtr:id>415EB9C1-81F0-4C8F-B1D7-486C595E31EE</gtr:id><gtr:outcomeId>58a583a54c1389.70012137</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2016-07-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>The findings from this study have resulted in four patent applications &amp;quot;Kit and method for quantitative detection of steroids&amp;quot; Application No. GB1215924.0; &amp;quot;Compound and Method for the Treatment of Neurodegenerative Conditions&amp;quot; Application No. GB1303589.4; &amp;quot;Deuterated compounds&amp;quot; Application No. GB 1316050.2; and &amp;quot;Diagnostic methods and kits&amp;quot; Application No. GB1516441.1. 5. &amp;quot;Diagnostic Methods and Kits&amp;quot; Application No.GB2016/052710. Our discovery of chenodeoxycholic acid as a treatment for oxysterol 7alpha-hydroxylase deficiency has prompted clinical trials. The methodology developed in this award is being used to support the clinical trials.</gtr:description><gtr:firstYearOfImpact>2013</gtr:firstYearOfImpact><gtr:id>BA2949E3-BB97-46B4-BE39-7D28C418979D</gtr:id><gtr:impactTypes><gtr:impactType>Economic</gtr:impactType></gtr:impactTypes><gtr:outcomeId>5453a6e08ed716.41601387</gtr:outcomeId><gtr:sector>Healthcare,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>The present invention relates to a compound and method for the treatment of neurodegenerative conditions and in particular but not exclusively to the use of a cholestenoic acid to treat neurodegenerative conditions such as Parkinson's disease and motor neuron disease.</gtr:description><gtr:grantRef>BB/I001735/1</gtr:grantRef><gtr:id>1493CD0B-2253-411A-8DFB-F4121B88AA13</gtr:id><gtr:impact>Impact has yet to arrive.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>m-4787695002.5443877668c604</gtr:outcomeId><gtr:patentId>WO2014132052</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Compound and method for the treatment of neurodegenerative conditions</gtr:title><gtr:yearProtectionGranted>2014</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Diagnostic method for identification of an inborn error of cholesterol biosynthesis.</gtr:description><gtr:grantRef>BB/I001735/1</gtr:grantRef><gtr:id>5499B16D-A044-492C-B74A-9983BDB83BDE</gtr:id><gtr:impact>Patent application has been made.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>56c6fd2a9a2221.87214155</gtr:outcomeId><gtr:patentId>GB1611636.0</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Diagnostic methods and kits</gtr:title><gtr:yearProtectionGranted>2016</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Compounds of general formula (I) wherein (I) R1 - R4 are each independently selected from H and deuterium; and at least one of R1 - R4 is deuterium. The compounds have been found to be particularly useful for treating neurodegenerative conditions and in particular but not exclusively conditions such as motor neurone disease.</gtr:description><gtr:grantRef>BB/I001735/1</gtr:grantRef><gtr:id>2C69F845-F6E9-494C-A589-260729693AA5</gtr:id><gtr:impact>Impact has yet to arise.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>m-7243527944.4265447668c6ae</gtr:outcomeId><gtr:patentId>WO2015036726</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>DEUTERATED COMPOUNDS</gtr:title><gtr:yearProtectionGranted>2015</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The present invention relates to a kit for the quantitative detection of steroids and to methods for using the kit. In particular, the method relates to a kit which enables steroids to be quantitatively detected using mass spectrometry.</gtr:description><gtr:grantRef>BB/I001735/1</gtr:grantRef><gtr:id>679E3663-D97D-4C28-BB25-5992FC17D7AC</gtr:id><gtr:impact>The discovery has been exploited for academic work.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>m-8898315791.8772817668c55a</gtr:outcomeId><gtr:patentId>UK Application GB1215924.0</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>KIT AND METHOD FOR QUANTITATIVE DETECTION OF STEROIDS</gtr:title></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The invention relates to a kit and methods for quantitative detection of steroids in a sample. The kit comprises quantitative charge tags and an oxidising agent.</gtr:description><gtr:grantRef>BB/I001735/1</gtr:grantRef><gtr:id>94D3CCE7-D3A5-4EC4-88AA-5F5EAD1A2982</gtr:id><gtr:impact>The kit will be commercialised by Avanti Polar Lipids</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>58aad941253b62.55977389</gtr:outcomeId><gtr:patentId>WO2014037725</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>KIT AND METHOD FOR QUANTITATIVE DETECTION OF STEROIDS</gtr:title><gtr:yearProtectionGranted>2014</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:keyFindingsOutput><gtr:description>Below we describe the objectives of the project and the progress made:
A. Create a series of isotope-coded charge tags for use in ultra-high sensitivity quantitative (absolute and relative) lipidomics. We have achieved this objective and applied for a patent:- &amp;quot;Kit and method for quantitative detection of steroids&amp;quot; Application No. GB1215924.0. We have described the method at international meetings (2nd ENOR Symposium, Oxysterols and Related Sterols in Chemistry, Biology and Medicine, Dijon 20-21 September 2012; and 20th International Mass Spectrometry Conference, Geneva, August 24-29, 2014). The method is published in Clinical Chemistry 2014. 
B. Exemplify the developed LC-MSn platform in the discovery and quantification of oxysterols/bile acids/steroids in biological fluids, tissues and specific cells types. Through collaboration with clinicians we have exploited our methodology in the comprehensive profiling of plasma sterols, with particular reference to inborn errors of metabolism. We have used the method to provide biochemical support to our discovery that chenodeoxycholic acid can be successfully used in the treatment of oxysterol 7alpha-hydroxylase deficiency. In collaboration with a pharmaceutical company we performed similar studies on cerebrospinal fluid (CSF) from patients suffering neural inflammation. We have further exploited our methodology for oxysterol analysis in tissues and in virus infected cells. This work has resulted in publications in Journal of Lipid Research, Journal of Inherited Metabolic Disease and in the journal Immunity. We have 

C. Generate a LC-MSn library of charge-tagged oxysterols/bile acids/steroids for use by the lipidomic and metabolomic communities. The library can be found at http://sterolanalysis.org.uk/?page=Home

D. Through collaboration with colleagues in Karolinska Institutet we investigate whether the identified compounds activate nuclear receptors in relevant cell systems. In collaboration with colleagues in Karolinska Institutet we have identified cholic acid as a new LXR ligand in brain and 24S,25-epoxycholesterol as the most abundant LXR ligand in developing mouse midbrain. Notably, each ligand selectively regulated the development of distinct midbrain neuronal populations. Whereas cholic acid increased survival and neurogenesis of Brn3a-positive red nucleus neurons, 24S,25-epoxycholesterol promoted dopaminergic neurogenesis. These results identify an entirely new class of highly selective and cell type-specific regulators of neurogenesis and neuronal survival. Moreover, 24S,25-epoxycholesterol promoted dopaminergic differentiation of embryonic stem cells, suggesting that LXR ligands may thus contribute to the development of cell replacement and regenerative therapies for Parkinson's disease. This study was published in the journal Nature Chemical Biology. In a related study on human we have identified 3?,7a-dihydroxycholest-5-en-26-oic acid as an LXR ligand which promotes the survival of oculomotor neurons. We have made a patent application &amp;quot;Compound and Method for the Treatment of Neurodegenerative Conditions&amp;quot; Application No. GB1303589.4 to protect these discoveries. The study is published in the Journal of Clinical Investigation.</gtr:description><gtr:exploitationPathways>1. We have collaborated with a pharmaceutical company on a project where our isotope-coded charge tags were directly utilized. 2. We have licenced our isotope-coded charge tags to Avanti Polar Lipids Inc. 3. The discovery of LXR ligands as cell type-specific regulators of neurogenesis and neuronal survival may lead to potential treatments for conditions such as Parkinson's disease and motor neuron disease. 4. To-date, the key activity towards exploiting the impact of our discoveries is through the patent applications &amp;quot;Kit and method for quantitative detection of steroids&amp;quot; and &amp;quot;Compound and Method for the Treatment of Neurodegenerative Conditions&amp;quot;. 5. Our discovery of chenodeoxycholic acid as a treatment for oxysterol 7alpha-hydroxylase deficiency has lead to the initiation of clinical trials. 6. We have discovered a novel inhibitor for the Hedgehog signalling pathway.</gtr:exploitationPathways><gtr:id>69B96C48-C6CE-4562-BA65-BDC33A118780</gtr:id><gtr:outcomeId>r-8981573021.953527774ffa94</gtr:outcomeId><gtr:sectors><gtr:sector>Chemicals,Healthcare,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors><gtr:url>http://sterolanalysis.org.uk/?page=Home</gtr:url></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>The drug is in clinical trials.</gtr:description><gtr:id>8BE487D6-46EA-4729-AC6D-F52A83718DC1</gtr:id><gtr:impact>The drug is in clinical trials for the treatment of a rare disease.</gtr:impact><gtr:outcomeId>56c6fec3e62592.58865140</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>CYP7B1</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2016</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>Collection of sterol mass spectrometry data (MS3).</gtr:description><gtr:id>C0D53F13-7220-46CB-85DB-FC97A9FC326D</gtr:id><gtr:impact>The database has been used by researchers using the EADSA technology developed in Swansea.</gtr:impact><gtr:outcomeId>58bec7c4e30836.12268729</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Sterolanalysis</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:url>http://sterolanalysis.org.uk/</gtr:url><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We have developed a charge-tagging approach to greatly enhance mass spectrometry sensitivity for biomolecule analysis.</gtr:description><gtr:id>2BEEC2E9-83F4-4B52-9596-46B2CBC7132A</gtr:id><gtr:impact>Allowed the identification of novel cholesterol metabolites in biological systems.</gtr:impact><gtr:outcomeId>545b5af34025e2.04667728</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>EADSA</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2011</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>Cholestenix</gtr:companyName><gtr:description>The Technology
Swansea Innovations has developed an integrated Mass Spectroscopy (MS) platform for the quantitative and structural determination of cholesterol metabolites in biological systems. The Liquid Chromatography (LC) MS technology utilises quantitative charged tags that allows for the identification of steroid molecules. The technology is substantially more sensitive than existing methodologies with a capacity to quantify a greater number of steroids.
The Science
The research group at Swansea Innovations have established that endogenous acidic cholesterol metabolites can have a neuroprotective and a neurotoxic effect on motor neurons. 
The Market
Swansea inventors have focussed on the medical opportunities for this technology as they have identified acidic cholesterol metabolites with neuroprotective activity and also abnormal cholesterol metabolite levels in a range of neurodegenerative diseases. Cerebrotendinous xanthomatosis (CTX) is an inherited disease in which affected individuals cannot make the normal profile of bile acids. As children grow older they may present with a range of symptoms including cataracts, abnormal movements, intellectual disability and cholesterol deposits in the brain. In conjunction with the Karolinska Institutet in Sweden, Swansea researchers have shown that plasma samples from patients with CTX showed very low levels of all cholestenoic acids. Further, abnormal cholesterol profiles have been identified in the Motor Neuron Disease (MND)- related illness, hereditary spastic paresis. A spin out company CholesteniX has been formed to commercialise the biomarker and therapeutic potential of this technology for MND and other neurodegenerative diseases. Swansea is in discussions with a number of commercial parties who have expressed an interest in this technology. The consensus view now is that most neurodegenerative diseases (e.g. Alzheimer's and Parkinson's disease) may be developing for anything up to decades before physical symptoms start to appear. Early diagnosis and treatment in this area may hold out the hope of slowing progression sufficiently to avoid late stage disease, saving the NHS and the economy millions of pounds in treatment and care and benefiting many thousands families with affected individuals.</gtr:description><gtr:id>6048A93F-6417-42C0-9526-0CB7B7C9FE4B</gtr:id><gtr:impact>none as yet</gtr:impact><gtr:outcomeId>5696391d8f5c05.47719884</gtr:outcomeId><gtr:yearCompanyFormed>2013</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication><gtr:id>327157FE-EBE7-4544-A268-6EC6795FA9C6</gtr:id><gtr:title>Quantitative charge-tags for sterol and oxysterol analysis.</gtr:title><gtr:parentPublicationTitle>Clinical chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4ada2f6d476b7c02c388615661e61357"><gtr:id>4ada2f6d476b7c02c388615661e61357</gtr:id><gtr:otherNames>Crick PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0009-9147</gtr:issn><gtr:outcomeId>doi_55fa9ea9e39846c4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AF6FF1AF-951D-406F-9E85-390626D103A7</gtr:id><gtr:title>24S,25-Epoxycholesterol in mouse and rat brain.</gtr:title><gtr:parentPublicationTitle>Biochemical and biophysical research communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/52542eaf317f347220ec706e5b20b4a1"><gtr:id>52542eaf317f347220ec706e5b20b4a1</gtr:id><gtr:otherNames>Wang Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-291X</gtr:issn><gtr:outcomeId>5450e47797ba55.89774274</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3503258C-01C9-46EF-AFF0-1FABF38BFB64</gtr:id><gtr:title>Analysis of bioactive oxysterols in newborn mouse brain by LC/MS.</gtr:title><gtr:parentPublicationTitle>Journal of lipid research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d5848cd682f2c1ccac5382b7a69c244f"><gtr:id>d5848cd682f2c1ccac5382b7a69c244f</gtr:id><gtr:otherNames>Meljon A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-2275</gtr:issn><gtr:outcomeId>5450fb02e73744.39448499</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>43BBC19C-7C03-4794-A462-C26071E8B352</gtr:id><gtr:title>Effects of a disrupted blood-brain barrier on cholesterol homeostasis in the brain.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6a490cd70d188905f7f97003c0c15341"><gtr:id>6a490cd70d188905f7f97003c0c15341</gtr:id><gtr:otherNames>Saeed AA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>5675db06772c7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4A1254B1-1FD2-4C37-802C-2593A64CEE8A</gtr:id><gtr:title>Comparison of the composition of bile acids in bile of patients with adenocarcinoma of the pancreas and benign disease.</gtr:title><gtr:parentPublicationTitle>The Journal of steroid biochemistry and molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/abf6caa79dd05d0940be0e9f1c400915"><gtr:id>abf6caa79dd05d0940be0e9f1c400915</gtr:id><gtr:otherNames>Rees DO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0960-0760</gtr:issn><gtr:outcomeId>5a2fce26837488.03123463</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C931712C-4364-4D3A-8645-ED6B6F612A4B</gtr:id><gtr:title>Defective cholesterol metabolism in amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Journal of lipid research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/431a767937725fdd7cabdb422318cce0"><gtr:id>431a767937725fdd7cabdb422318cce0</gtr:id><gtr:otherNames>Abdel-Khalik J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0022-2275</gtr:issn><gtr:outcomeId>58a43e36680841.00804075</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>513E73A6-809B-4D0F-9F8E-2C4BCA32AC9A</gtr:id><gtr:title>Analysis by liquid chromatography-mass spectrometry of sterols and oxysterols in brain of the newborn Dhcr7(&amp;Icirc;?3-5/T93M) mouse: a model of Smith-Lemli-Opitz syndrome.</gtr:title><gtr:parentPublicationTitle>Biochemical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d5848cd682f2c1ccac5382b7a69c244f"><gtr:id>d5848cd682f2c1ccac5382b7a69c244f</gtr:id><gtr:otherNames>Meljon A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-2952</gtr:issn><gtr:outcomeId>5450f11126cb59.38179871</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F8E46C6F-D9D3-49EA-B13D-CA37F4608C1F</gtr:id><gtr:title>Nano-liquid chromatography-tandem mass spectrometry analysis of oxysterols in brain: monitoring of cholesterol autoxidation.</gtr:title><gtr:parentPublicationTitle>Chemistry and physics of lipids</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/db630568786f5f5028f8b0d06e2c4826"><gtr:id>db630568786f5f5028f8b0d06e2c4826</gtr:id><gtr:otherNames>Karu K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0009-3084</gtr:issn><gtr:outcomeId>5451000f5ec8d5.93921360</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BA6E1CB8-7B6F-4F5F-88E1-42185CFE85D8</gtr:id><gtr:title>Analytical strategies for characterization of oxysterol lipidomes: liver X receptor ligands in plasma.</gtr:title><gtr:parentPublicationTitle>Free radical biology &amp; medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6a8639bfaacb7b92b3e175f6a81253b8"><gtr:id>6a8639bfaacb7b92b3e175f6a81253b8</gtr:id><gtr:otherNames>Griffiths WJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0891-5849</gtr:issn><gtr:outcomeId>5450fdc997bce0.22726800</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7574C640-8FBD-4E2F-BCF6-69206F475D88</gtr:id><gtr:title>Oxysterols in the brain of the cholesterol 24-hydroxylase knockout mouse.</gtr:title><gtr:parentPublicationTitle>Biochemical and biophysical research communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d5848cd682f2c1ccac5382b7a69c244f"><gtr:id>d5848cd682f2c1ccac5382b7a69c244f</gtr:id><gtr:otherNames>Meljon A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-291X</gtr:issn><gtr:outcomeId>5450ed4f0cf8f1.03277474</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>067B44A6-C799-447B-B601-78547A99997A</gtr:id><gtr:title>Cholestenoic acids regulate motor neuron survival via liver X receptors.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2493a512c6a8a8df4c52f46edeac1d27"><gtr:id>2493a512c6a8a8df4c52f46edeac1d27</gtr:id><gtr:otherNames>Theofilopoulos S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn><gtr:outcomeId>544f87573ede68.56841641</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>37638844-F072-4EE2-A2BB-B5AD3EE78332</gtr:id><gtr:title>Sterols and oxysterols in plasma from Smith-Lemli-Opitz syndrome patients.</gtr:title><gtr:parentPublicationTitle>The Journal of steroid biochemistry and molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6a8639bfaacb7b92b3e175f6a81253b8"><gtr:id>6a8639bfaacb7b92b3e175f6a81253b8</gtr:id><gtr:otherNames>Griffiths WJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0960-0760</gtr:issn><gtr:outcomeId>585d35c064c174.96688057</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6B22D8D9-B631-4C8B-BC25-769F85A28858</gtr:id><gtr:title>Current trends in oxysterol research.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6a8639bfaacb7b92b3e175f6a81253b8"><gtr:id>6a8639bfaacb7b92b3e175f6a81253b8</gtr:id><gtr:otherNames>Griffiths WJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn><gtr:outcomeId>585d707a096c07.49324957</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>98D3F6CF-CCF9-47D7-AC59-F3FEBDF7001B</gtr:id><gtr:title>Studies on the analysis of 25-hydroxyvitamin D(3) by isotope-dilution liquid chromatography-tandem mass spectrometry using enzyme-assisted derivatisation.</gtr:title><gtr:parentPublicationTitle>Biochemical and biophysical research communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/431a767937725fdd7cabdb422318cce0"><gtr:id>431a767937725fdd7cabdb422318cce0</gtr:id><gtr:otherNames>Abdel-Khalik J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-291X</gtr:issn><gtr:outcomeId>5450ee4df051d7.61507796</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3A59C810-534C-4C6F-8983-63E4F6E58013</gtr:id><gtr:title>Brain endogenous liver X receptor ligands selectively promote midbrain neurogenesis.</gtr:title><gtr:parentPublicationTitle>Nature chemical biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2493a512c6a8a8df4c52f46edeac1d27"><gtr:id>2493a512c6a8a8df4c52f46edeac1d27</gtr:id><gtr:otherNames>Theofilopoulos S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1552-4450</gtr:issn><gtr:outcomeId>5450f35a929e94.09898747</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EB9FC492-7E41-494E-A324-E0A97453429B</gtr:id><gtr:title>Methods for oxysterol analysis: past, present and future.</gtr:title><gtr:parentPublicationTitle>Biochemical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6a8639bfaacb7b92b3e175f6a81253b8"><gtr:id>6a8639bfaacb7b92b3e175f6a81253b8</gtr:id><gtr:otherNames>Griffiths WJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-2952</gtr:issn><gtr:outcomeId>5450f243c240f3.77089599</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>88FDF8A0-2A0C-4C79-86B5-E383746D3C32</gtr:id><gtr:title>Role of AMACR (a-methylacyl-CoA racemase) and MFE-1 (peroxisomal multifunctional enzyme-1) in bile acid synthesis in mice.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/368ed1577e3ac86ec0fd4cbb172eefff"><gtr:id>368ed1577e3ac86ec0fd4cbb172eefff</gtr:id><gtr:otherNames>Autio KJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>5450eab7e6c940.35766561</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F29B1146-A9B7-4AB5-BBC3-F6BD98AA3605</gtr:id><gtr:title>New methods for analysis of oxysterols and related compounds by LC-MS.</gtr:title><gtr:parentPublicationTitle>The Journal of steroid biochemistry and molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6a8639bfaacb7b92b3e175f6a81253b8"><gtr:id>6a8639bfaacb7b92b3e175f6a81253b8</gtr:id><gtr:otherNames>Griffiths WJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0960-0760</gtr:issn><gtr:outcomeId>5694fe0441f052.14313925</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5A0DEC42-1F12-4AF0-96D7-4A7FE3E3F17A</gtr:id><gtr:title>Liver disease in infancy caused by oxysterol 7 a-hydroxylase deficiency: successful treatment with chenodeoxycholic acid.</gtr:title><gtr:parentPublicationTitle>Journal of inherited metabolic disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1a338989e9d8b7444b3c93382b2442f7"><gtr:id>1a338989e9d8b7444b3c93382b2442f7</gtr:id><gtr:otherNames>Dai D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0141-8955</gtr:issn><gtr:outcomeId>5450eb409759e2.65374311</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6EE60B99-B432-4B9F-96BA-85A0E92FB9A2</gtr:id><gtr:title>The oxysterol and cholestenoic acid profile of mouse cerebrospinal fluid.</gtr:title><gtr:parentPublicationTitle>Steroids</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4ada2f6d476b7c02c388615661e61357"><gtr:id>4ada2f6d476b7c02c388615661e61357</gtr:id><gtr:otherNames>Crick PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0039-128X</gtr:issn><gtr:outcomeId>569500ae42d353.89092155</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3387BB41-B580-407D-BA63-06E0A910F259</gtr:id><gtr:title>The role of microRNA-155/liver X receptor pathway in experimental and idiopathic pulmonary fibrosis.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c46e2ecdbdcf081c5e7884ac05702bb5"><gtr:id>c46e2ecdbdcf081c5e7884ac05702bb5</gtr:id><gtr:otherNames>Kurowska-Stolarska M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>58a43ebb3c2113.40158808</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DE32AE96-A3A5-4B11-8EFD-45BF54AF985B</gtr:id><gtr:title>Revised sample preparation for the analysis of oxysterols by enzyme-assisted derivatisation for sterol analysis (EADSA).</gtr:title><gtr:parentPublicationTitle>Analytical and bioanalytical chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4ada2f6d476b7c02c388615661e61357"><gtr:id>4ada2f6d476b7c02c388615661e61357</gtr:id><gtr:otherNames>Crick PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1618-2642</gtr:issn><gtr:outcomeId>5675e12d99190</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>91E4DA44-1A22-455E-840D-D6FFD2412843</gtr:id><gtr:title>A comprehensive machine-readable view of the mammalian cholesterol biosynthesis pathway.</gtr:title><gtr:parentPublicationTitle>Biochemical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8fce1da3e9dd7563fb7c961153d7a4d9"><gtr:id>8fce1da3e9dd7563fb7c961153d7a4d9</gtr:id><gtr:otherNames>Mazein A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-2952</gtr:issn><gtr:outcomeId>5450ef99867c08.70132166</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>15C6DA24-E0DC-4C10-9AE7-0500D2C173FB</gtr:id><gtr:title>On the formation of 7-ketocholesterol from 7-dehydrocholesterol in patients with CTX and SLO.</gtr:title><gtr:parentPublicationTitle>Journal of lipid research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/97af4027ddc3aa2a1d7480a786b1bd21"><gtr:id>97af4027ddc3aa2a1d7480a786b1bd21</gtr:id><gtr:otherNames>Bj?rkhem I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-2275</gtr:issn><gtr:outcomeId>5450ea59c644c8.84083537</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D248C119-304E-4842-9137-042B42A83A21</gtr:id><gtr:title>Cholesterolomics: An update.</gtr:title><gtr:parentPublicationTitle>Analytical biochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6a8639bfaacb7b92b3e175f6a81253b8"><gtr:id>6a8639bfaacb7b92b3e175f6a81253b8</gtr:id><gtr:otherNames>Griffiths WJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0003-2697</gtr:issn><gtr:outcomeId>58a43d9aa5f678.22944215</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B37A79D8-725D-4162-B9DD-98BB94E845EF</gtr:id><gtr:title>Analysis of oxysterol metabolomes.</gtr:title><gtr:parentPublicationTitle>Biochimica et biophysica acta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6a8639bfaacb7b92b3e175f6a81253b8"><gtr:id>6a8639bfaacb7b92b3e175f6a81253b8</gtr:id><gtr:otherNames>Griffiths WJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0006-3002</gtr:issn><gtr:outcomeId>5450ff2496bb46.23268824</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FEFE8608-DAE5-4459-B951-A39BB9565765</gtr:id><gtr:title>Charge-tagging liquid chromatography-mass spectrometry methodology targeting oxysterol diastereoisomers.</gtr:title><gtr:parentPublicationTitle>Chemistry and physics of lipids</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6a8639bfaacb7b92b3e175f6a81253b8"><gtr:id>6a8639bfaacb7b92b3e175f6a81253b8</gtr:id><gtr:otherNames>Griffiths WJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0009-3084</gtr:issn><gtr:outcomeId>5a2fcde09e7768.43138684</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ADF1600E-8FAE-410D-B776-C352217CFCB5</gtr:id><gtr:title>Reduced Plasma Levels of 25-Hydroxycholesterol and Increased Cerebrospinal Fluid Levels of Bile Acid Precursors in Multiple Sclerosis Patients.</gtr:title><gtr:parentPublicationTitle>Molecular neurobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4ada2f6d476b7c02c388615661e61357"><gtr:id>4ada2f6d476b7c02c388615661e61357</gtr:id><gtr:otherNames>Crick PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0893-7648</gtr:issn><gtr:outcomeId>58a43c70a3db91.04326964</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AE8F12D4-82C1-4C34-86AB-659FFAFF99CF</gtr:id><gtr:title>The transcription factor STAT-1 couples macrophage synthesis of 25-hydroxycholesterol to the interferon antiviral response.</gtr:title><gtr:parentPublicationTitle>Immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bdac57e10fe451b27d607f9816f9f25f"><gtr:id>bdac57e10fe451b27d607f9816f9f25f</gtr:id><gtr:otherNames>Blanc M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1074-7613</gtr:issn><gtr:outcomeId>5450f74927cec7.14434767</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>900BD342-C339-476B-8DC2-AF923685D86E</gtr:id><gtr:title>Shotgun cholanomics of ileal fluid.</gtr:title><gtr:parentPublicationTitle>Biochimie</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aabb4a3c08d22654d635504cdccd286f"><gtr:id>aabb4a3c08d22654d635504cdccd286f</gtr:id><gtr:otherNames>Chen Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0300-9084</gtr:issn><gtr:outcomeId>5450fa3dcdd556.56070893</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B5855594-AF13-4927-BB91-BECE8A9D5CCC</gtr:id><gtr:title>Cholesterol metabolites exported from human brain.</gtr:title><gtr:parentPublicationTitle>Steroids</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e6feff05a3deef5acee97cd61d2d3b79"><gtr:id>e6feff05a3deef5acee97cd61d2d3b79</gtr:id><gtr:otherNames>Iuliano L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0039-128X</gtr:issn><gtr:outcomeId>5675df9952e1a</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>80D9197C-CB8E-427E-AAEC-6D75602822E4</gtr:id><gtr:title>An update on oxysterol biochemistry: New discoveries in lipidomics.</gtr:title><gtr:parentPublicationTitle>Biochemical and biophysical research communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6a8639bfaacb7b92b3e175f6a81253b8"><gtr:id>6a8639bfaacb7b92b3e175f6a81253b8</gtr:id><gtr:otherNames>Griffiths WJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0006-291X</gtr:issn><gtr:outcomeId>5a981e685b8a27.05923867</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5A9A6D52-401D-49EC-BDA2-AC2272F5B812</gtr:id><gtr:title>Evaluation of novel derivatisation reagents for the analysis of oxysterols.</gtr:title><gtr:parentPublicationTitle>Biochemical and biophysical research communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4ada2f6d476b7c02c388615661e61357"><gtr:id>4ada2f6d476b7c02c388615661e61357</gtr:id><gtr:otherNames>Crick PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-291X</gtr:issn><gtr:outcomeId>5450ebde9f49d7.77030601</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>676FD44E-039C-43B0-BF67-2C457EE1119B</gtr:id><gtr:title>Sterolomics: State of the art, developments, limitations and challenges.</gtr:title><gtr:parentPublicationTitle>Biochimica et biophysica acta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6a8639bfaacb7b92b3e175f6a81253b8"><gtr:id>6a8639bfaacb7b92b3e175f6a81253b8</gtr:id><gtr:otherNames>Griffiths WJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0006-3002</gtr:issn><gtr:outcomeId>5a2fcddd101e62.83251301</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9C1FEE3B-15FA-489E-BC9F-3927B785D551</gtr:id><gtr:title>Shorthand notation for lipid structures derived from mass spectrometry.</gtr:title><gtr:parentPublicationTitle>Journal of lipid research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6ba4d51000be4d34490b39525f7b71c2"><gtr:id>6ba4d51000be4d34490b39525f7b71c2</gtr:id><gtr:otherNames>Liebisch G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-2275</gtr:issn><gtr:outcomeId>5450f0a7e406f5.46235451</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BB/I001735/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>